Skip to main content
Hanna Sanoff, MD, Oncology, Chapel Hill, NC

HannaKSanoffMD

Oncology Chapel Hill, NC

Gastrointestinal Cancer

Associate Professor of Medicine, University of North Carolina at Chapel Hill

Dr. Sanoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sanoff's full profile

Already have an account?

  • Office

    170 Manning Dr Cb 7305
    Chapel Hill, NC 27599

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2003 - 2006
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2000 - 2003
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2000
  • University of North Carolina
    University of North CarolinaMPH

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2000 - 2025
  • VA State Medical License
    VA State Medical License 2009 - 2012
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients with Advanced Cancer  
    Andrea C Enzinger, Hanna Sanoff, Deborah Schrag, JAMA Oncology

Other

Authored Content

  • Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
  • Managing Grief, Loss, and Connection in Oncology—What COVID-19 Has TakenJuly 2020
  • Telemedicine for Cancer Care in the Time of COVID-19July 2020

Press Mentions

  • FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some Cancers
    FDA’s ODAC: Risks Outweigh Benefits for Checkpoint Inhibitors in Some CancersSeptember 30th, 2024
  • Carolina Cancer Experts Available for Interviews
    Carolina Cancer Experts Available for InterviewsMay 19th, 2023
  • Scientists Intrigued by Treatment That Put Every Single Patient's Cancer into Remission
    Scientists Intrigued by Treatment That Put Every Single Patient's Cancer into RemissionAugust 11th, 2022
  • Join now to see all

Professional Memberships